1. Home
  2. SITM vs CARM Comparison

SITM vs CARM Comparison

Compare SITM & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SITM
  • CARM
  • Stock Information
  • Founded
  • SITM 2003
  • CARM 2016
  • Country
  • SITM United States
  • CARM United States
  • Employees
  • SITM N/A
  • CARM N/A
  • Industry
  • SITM Semiconductors
  • CARM Biotechnology: Pharmaceutical Preparations
  • Sector
  • SITM Technology
  • CARM Health Care
  • Exchange
  • SITM Nasdaq
  • CARM Nasdaq
  • Market Cap
  • SITM N/A
  • CARM 7.7M
  • IPO Year
  • SITM 2019
  • CARM N/A
  • Fundamental
  • Price
  • SITM $196.07
  • CARM $0.19
  • Analyst Decision
  • SITM Strong Buy
  • CARM Hold
  • Analyst Count
  • SITM 5
  • CARM 5
  • Target Price
  • SITM $215.00
  • CARM $0.90
  • AVG Volume (30 Days)
  • SITM 272.0K
  • CARM 952.4K
  • Earning Date
  • SITM 05-07-2025
  • CARM 05-13-2025
  • Dividend Yield
  • SITM N/A
  • CARM N/A
  • EPS Growth
  • SITM N/A
  • CARM N/A
  • EPS
  • SITM N/A
  • CARM N/A
  • Revenue
  • SITM $229,989,000.00
  • CARM $19,964,000.00
  • Revenue This Year
  • SITM $38.41
  • CARM N/A
  • Revenue Next Year
  • SITM $22.83
  • CARM N/A
  • P/E Ratio
  • SITM N/A
  • CARM N/A
  • Revenue Growth
  • SITM 65.85
  • CARM 32.45
  • 52 Week Low
  • SITM $105.40
  • CARM $0.14
  • 52 Week High
  • SITM $268.18
  • CARM $1.90
  • Technical
  • Relative Strength Index (RSI)
  • SITM 59.19
  • CARM 44.76
  • Support Level
  • SITM $195.08
  • CARM $0.14
  • Resistance Level
  • SITM $203.67
  • CARM $0.20
  • Average True Range (ATR)
  • SITM 8.38
  • CARM 0.02
  • MACD
  • SITM -1.80
  • CARM 0.00
  • Stochastic Oscillator
  • SITM 34.88
  • CARM 71.47

About CARM Carisma Therapeutics Inc.

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Share on Social Networks: